- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01732640
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV-Negative or High-risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC
Trial Objectives:
The objective is to investigate the efficacy and safety of afatinib with induction chemotherapy in primary unresected patients with locally advanced, HPV-negative, stage III or IVa/b HNSCC including oral cavity, oropharynx, hypopharynx, or larynx.
Primary Objective Phase I The primary objective of the phase I portion of the trial is to determine the maximum tolerated dose (MTD) or the recommended phase II dose of daily oral afatinib that is safe in combination with carboplatin AUC 6 and paclitaxel 175mg/m2 q 21 days as an induction regimen.
Primary Objective Phase 2 The primary objective of the phase 2 portion of the trial is to estimate the objective tumor response rate and toxicity with induction therapy in patients treated on the afatinib dose determined in Phase I.
Secondary Objectives The secondary objective of phase II is to estimate: 1) the overall response to entire treatment after completion of CRT, 2) progression-free survival (PFS) rate at 2 years, and 3) overall survival (OS) at 2 years.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This is a phase I/phase II prospective multicenter trial to investigate the efficacy and safety of afatinib with induction chemotherapy in primary unresected patients with HPV-negative locally advanced SCC stage III or IVa/b of oral cavity, oropharynx, hypopharynx, or larynx. The primary endpoint is overall response rate after the completion of induction chemotherapy.
Eligible patients will begin with a 14 day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy with carboplatin AUC 6 IV, paclitaxel 175mg/m2 day 1, and afatinib as a continuous daily dosing. Each cycle is repeated every 21 days. All patients will receive concurrent chemoradiotherapy beginning 2-3 weeks after the completion of the second cycle of induction chemotherapy (Refer to Study Schema in page 8 of the protocol).
During the period of induction chemotherapy, a complete history and physical (including weight) and tumor assessment by physical examination on Day 1 of each cycle will be performed and documented. Complete blood count with differential and a comprehensive metabolic profile will be performed weekly. After completion of induction chemotherapy, reassessment with blood work, physical exam, CT/MRI of neck and nasopharyngolaryngoscopy will be performed. After the completion of CRT, the patient will have a MRI, CT, or FDG PET approximately 12 weeks after CRT. Follow-up will be standard of care from this point onwards.
Physical exam, blood work and AE assessments will also be frequently performed during entire treatment.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Vanderbilt Ingram Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients must have a histologically confirmed diagnosis of squamous cell carcinoma, operable or inoperable tumors, stage III (T3N0-1) and IVA-B (T1-4 N2-3M0 or T4N0-1M0) of oral cavity, oropharynx, hypopharynx and larynx. For patients with oropharynx primary, either HPV negative or HPV positive with a > 10 pack year tobacco history or current smokers are eligible. HPV status should be determined before the enrollment in only non-smokers with oropharynx primary by HPV in-situ hybridization and/or p16 immunostain.
- Patients must have measurable disease of primary, nodes or both by clinical and radiographic methods per RECIST v1.1..
- No prior therapy, including surgery with curative intent, chemotherapy, radiation therapy, immunotherapy, EGFR targeted therapies, or any other investigational agents.
- Age >= 18 years.
- ECOG performance status 0-1.
Patients must have normal hepatic, renal and bone marrow function.
- Absolute neutrophil count >=1,000/ mm3 Count
- Platelets >= 100,000/mm3 Count
- Total serum bilirubin =< 1.5mg/dL Level:
- AST and ALT =< 2.5 X ULN
- Alkaline Phosphatase =< 2.5 X ULN
- Total calculated creatinine clearance >= 60 mL/min
- Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer.
Patients with the following within the last 6 months prior to pre-registration must be evaluated by a cardiologist and/or neurologist prior to entry into the study.
- Congestive heart failure > NYHA Class II
- CVA/TIA
- Unstable angina
- Myocardial infarction (with or without ST elevation)
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Any prior radiation above the clavicles.
- Any prior invasive malignancy (unless non-melanomatous resectable skin or the DFS is 2 years or more).
- History of allergic reactions attributed to compounds of similar chemical or biological composition to afatinib, or other agents used in study.
- Cardiac left ventricular dysfunction with resting ejection fraction of less than institutional lower limit of normal ( if no lower limit of normal is defined in the institution, the lower limit is 50%)
- Gastrointestinal tract disease resulting in an inability to take or absorb oral or enteral medication.
- Baseline significant gastrointestinal symptoms with diarrhoea as a major symptom or a CTCAE Grade >1 diarrhoea of any etiology.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception.
- Known pre-existing interstitial lung disease (ILD)
- Pregnant women are excluded.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Study Arm
Eligible patients will begin with a 14-day lead-in period with afatinib alone.
This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing.
Each cycle is repeated every 21 days.
After completion of 2 cycles of IC, patients will be assessed for response by CT/MRI and clinical exam.
After the induction, all patients will receive Intensity Modulated Radiation Therapy (IMRT) with weekly cisplatin 40mg/m2 IV.
Chemoradiotherapy (CRT) will begin 2-3 weeks after the completion of the second cycle of IC.
The patients will be evaluated with a MRI or CT, and FDG PET approximately 12 weeks after completion of CRT.
|
Afatinib will be supplied as film-coated tablets.
Available dosage strengths will be 20, 30, or 40 mg.
Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
Autres noms:
Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
Autres noms:
Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin.
Each vial contains equal parts by weight of carboplatin and mannitol.
Commercial supplies of carboplatin will be used in this trial.
Autres noms:
Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
Autres noms:
Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Maximum Tolerated Dose (MTD) of Afatinib
Délai: 1 Year (Average)
|
The maximally tolerated dose (MTD) was defined as the dose of afatinib in which <2 of 6 patients experience a DLT with the next higher dose having at least 2 of up to 6 patients experiencing a DLT.
No dose escalations or de-escalations are permitted within each subject's treatment.
|
1 Year (Average)
|
Objective Tumor Response
Délai: After completion of 2 cycles of induction chemotherapy (at least 8 weeks)
|
Patients were accessed for response by CT/MRI and clinical exam.
Partial response was defined as a greater than 30 % reduction in tumor size.
|
After completion of 2 cycles of induction chemotherapy (at least 8 weeks)
|
Number of Participants With Dose Limiting Toxicities
Délai: 1 year (average)
|
Grade 3 or 4 neutropenia (ie.
absolute neutrophil count <1000 cells/mm^3) that was associated with a fever>38.5
degrees C or lasting longer than 5 days, grade 3 thrombocytopenia with bleeding or grade 4 thrombocytopenia, and any grade 3 or 4 non-hematologic toxicity per CTCAE criteria which were probably or definitely related to study therapy.
During the chemoradiation, an event of stomatitis, pharyngitis, mucositis, or dermatitis was not considered to be a dose limiting toxicity unless it was a grade 4 that did resolve to <grade 2 with a radiation treatment break (not to exceed 10 days) or with withholding chemotherapy (not to exceed 2 weekly doses).
|
1 year (average)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Overall Response After Chemoradiation
Délai: 5 Years
|
To estimate the overall response rate after completion of chemoradiation.
|
5 Years
|
2 Year Progression Free Survival (PFS)
Délai: 2 Years
|
To estimate the 2 year progression free survival.
|
2 Years
|
Median Overall Survival at 2 Years
Délai: 2 Years
|
To estimate the median overall survival.
|
2 Years
|
Biological Marker Activity of Afatinib
Délai: 5 Years
|
To estimate the biological marker activity of afatinib by serial sampling of tumor and blood samples from patients, and correlate with clinical and pathological response and outcomes.
On- and off-target effects of afatinib will be assessed for the biological marker activity.
|
5 Years
|
Activity of Afatinib Based on Serial FLT-PET/CT and DW-MRI
Délai: 5 Years
|
To estimate the activity of afatinib by obtaining serial FLT-PET/CT and DW-MRI, And compare to standard of care CT images (which will be acquired at baseline and at the completion of treatment, and categorized per RECIST criteria) and correlated with response.
|
5 Years
|
Correlate Standard Imaging Pre and Post Treatment
Délai: 5 Years
|
To correlate the response with standard imaging CT/MRI and FDG PET pre and post treatment.
|
5 Years
|
Overall Response After Chemoradiation
Délai: 5 years
|
To estimate the overall response rate after completion of chemoradiation
|
5 years
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Christine Chung, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs par site
- Carcinome
- Tumeurs, glandulaires et épithéliales
- Tumeurs de la tête et du cou
- Tumeurs à cellules squameuses
- Carcinome épidermoïde
- Carcinome épidermoïde de la tête et du cou
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Modulateurs de tubuline
- Agents antimitotiques
- Modulateurs de mitose
- Agents antinéoplasiques phytogéniques
- Inhibiteurs de protéine kinase
- Carboplatine
- Paclitaxel
- Cisplatine
- Afatinib
Autres numéros d'identification d'étude
- J1266
- NA_00074085 (Autre identifiant: JHMIRB)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Afatinib
-
Boehringer IngelheimComplété
-
Boehringer IngelheimComplétéCarcinome pulmonaire non à petites cellulesGrèce
-
Boehringer IngelheimComplétéTumeurs neuroectodermiques | RhabdomyosarcomeÉtats-Unis, Espagne, Canada, Allemagne, Italie, Royaume-Uni, Australie, L'Autriche, Danemark, Îles Féroé, France, Pays-Bas
-
Boehringer IngelheimApprouvé pour la commercialisation
-
Boehringer IngelheimComplétéCancer du poumon non épidermoïde et non à petites cellulesJapon
-
Boehringer IngelheimPlus disponible
-
Boehringer IngelheimComplétéCarcinome pulmonaire non à petites cellulesCorée, République de
-
National University Hospital, SingaporePas encore de recrutement
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RésiliéCarcinome épidermoïde de la tête et du couÉtats-Unis